Impact of exacerbations on copd

European Respiratory Review

Volumn 19, Issue 116, 2010, Pages 113-118

  Anzueto, A ^a  

^a 111E Pulmonary/critical care ^*  (United States)

Author keywords

Acute exacerbations; Chronic obstructive pulmonary disease; Pulmonary function; Quality of life

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; INFLUENZA VACCINE; LONG ACTING DRUG; PNEUMOCOCCUS VACCINE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; COST OF ILLNESS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; EMERGENCY WARD; EMOTIONAL DISORDER; EXERCISE; HEALTH CARE COST; HOSPITAL PATIENT; HUMAN; INCIDENCE; INTENSIVE CARE; LUNG FUNCTION; MORTALITY; PERFORMANCE; PHYSICAL DISABILITY; PRIMARY MEDICAL CARE; QUALITY OF LIFE; RESPIRATORY TRACT DISEASE; REVIEW; SOCIAL ASPECT;

COMORBIDITY; DISEASE PROGRESSION; HEALTH STATUS; HUMANS; INCIDENCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE;

EID: 77953196234     PISSN: 09059180     EISSN: None     Source Type: Journal    
DOI: 10.1183/09059180.00002610     Document Type: Review

References (76)

1. National Institutes of Health. National Heart, Lung, and Blood Institute. Morbidity and Mortality: 2002 Chart Book on Cardiovascular, Lung and Blood Diseases. Bethesda, National Heart, Lung, and Blood Institute, 2002. www.nhlbi.nih.gov/resources/docs/02_chtbk.pdf Date last accessed: September 19, 2002.
2. Mannino DM, Homa DM, Akinbami LJ, et al. Chronic obstructive pulmonary disease surveillance - United States, 1971-2000. MMWR Surveill Summ 2002; 51: 1-16.
3. GOLD Executive and Science Committees. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: GOLD Executive Summary updated 2009. www.gold-copd.org Date last accessed: January 24, 2010.
4. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176: 532-555.
5. Miravitlles M, Murio C, Guerrero T, et al. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest 2002; 121: 1449-1455.
6. Miravitlles M, Ferrer M, Pont A, et al. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax 2004; 59: 387-395.
7. Halpern MT, Stanford RH, Borker R. The burden of COPD in the USA: results from the confronting COPD survey. Respir Med 2003; 97: Suppl. C, S81-S89.
8. Miravitlles M, Guerrero T, Mayordomo C, et al. Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysis. The EOLO Study Group. Respiration 2000; 67: 495-501.
9. Burge PS, Calverley PMA, Jones PW, et al. Randomised, double blind, placebo-controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 20: 1297-1303.
10. Paggiaro PL, Dahle R, Bakran I, et al. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. Lancet 1998; 351: 773-780.
11. Donaldson GC, Seemungal TAR, Bhowmik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847-852.
12. Greenberg SB, Allen MA, Wilson J, et al. Respiratory viral infections in adults with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 162: 167-173.
13. Miravitlles M, Mayordomo C, Artés M, et al. Treatment of chronic obstructive pulmonary disease and its exacerbations in general practice. EOLO Group. Observational de la Limitacion Obstructiva al Flujo aEreo. Respir Med 1999; 93: 173-179.
14. Gompertz S, Bayley DL, Hill SL, et al. Relationship between airway inflammation and the frequency of exacerbations in patients with smoking related COPD. Thorax 2001; 56: 36-41
15. Decramer M, Celli B, Kesten S, et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmon- ary disease (UPLIFT): a prespecified subgroup analysis of a randomized controlled trial. Lancet 2009; 374: 1171-1178
16. Jenkins CR, Jones PW, Calverley PM, et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomized, placebo- controlled TORCH study. Respir Res 2009; 10: 59.
17. Kosmas EN, Zorpidou D, Vassilareas V, et al. Decreased C4 complement component serum levels correlate with the degree of emphysema in patients with chronic bronchitis. Chest 1997; 112: 341-347
18. Aaron SD, Vandemheen KL, Clinch JJ, et al. Measurment of short- term changes in dyspnoea and disease-specific quality of life following an acute COPD exacerbation. Chest 2002; 121: 688-696
19. Rutshmann OT, Cornuz J, Poletti PA, et al. Should pulmonary embolisms be suspected in exacerbation of chronic obstructive pulmonary disease? Thorax 2007; 62: 121-125
20. Tillie-Leblond I, Marquette CH, Perez T. Pulmonary embolism in patients with unexplained exacerbation of chronic obstructive pulmonary disease: prevalence and risk factors. Ann Intern Med 2006; 144: 390-396
21. Dewan NA, Rafique S, Kanwar B, et al. Acute exacerbation of COPD. Factors associated with poor outcome. Chest 2000; 117: 662-671
22. Adams SG, Melo J, Luther M, et al. Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD. Chest 2000; 117: 1345-1352
23. Murata GH, Gorby MS, Kapsner CO, et al. A multivariate model for predicting hospital admissions for patients with decompensate chronic obstructive pulmonary disease. Arch Intern Med 1992; 152: 82-86
24. Antonelli Incalzi R, Fuso L, De Rosa M, et al. Co-morbidity contributes to predict mortality of patients with chronic obstruc- tive pulmonary disease. Eur Respir J 1997; 10: 2794-2800
25. Vilkman S, Keistinen T, Tuuponen T, et al. Survival and cause of death among elderly chronic obstructive pulmonary disease patients after first admission to hospital. Respiration 1997; 64: 281-284
26. Pinto-Plata VM, Mullerova H, Toso JF, et al. C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax 2006; 61: 23-28
27. Dahl M, Tybjaerg-Hansen A, Vestbo J, et al. Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 1008-1011
28. Piehl-Aulin K, Jones I, Lindvall B, et al. Increased serum inflammatory markers in the absence of clinical and skeletal muscle inflammation in patients with chronic obstructive pul- monary disease. Respiration 2009; 78: 191-196
29. Eagan TML, Ueland T, Wagner PD, et al. Systemic inflammatory markers in COPD: results from the Bergen COPD cohort study. Eur Respir J 2010; 35: 540-548
30. Mortensen EM, Copeland LA, Pugh MJV, et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res 2009; 10: 45-54
31. Anzueto A, Leimer I, Kesten S. Impact of frequency of COPD exacerbations on pulmonary function, health status and clinical outcomes. Int J Chron Obstruct Pulmon Dis 2009; 4: 245-251
32. Spencer S, Jones PW, for the GLOBE Study Group, Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax 2003; 58: 589-593
33. Spencer S, Calverley PMA, Burge S, et al. Health status deteriora- tion in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163: 122-128
34. Donaldson GC, Wilkinson TM, Hurst JR, et al. Exacerbations and time spent outdoors in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 171: 446-452
35. Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacother- apy on rate of decline of lung function in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 178: 332-338
36. Connors AF Jr, Dawson NV, Thomas C, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med 1996; 154: 959-967
37. Seemungal TA, Donaldson GC, Bhowmik A, et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161: 1608-1613
38. Crooks SW, Bayley DL, Hill SL, et al. Bronchial inflammation in acute bacterial exacerbations of chronic bronchitis: the role of leukotriene B4. Eur Respir J 2000; 15: 274-280
39. Ras G, Wilson R, Todd H, et al. The effect of bacterial products on neutrophil migration in vitro. Thorax 1990; 45: 276-280
40. Stanescu D, Sanna A, Veriter C, et al. Airways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophils. Thorax 1996; 51: 267-271
41. Papi A, Bellettato CM, Braccioni F, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 2006; 173: 1114-1121
42. Zhu J, Qiu YS, Majumdar S, et al. Exacerbations of bronchitis: bronchial eosinophilia and gene expression for interleukin-4, interleukin-5, and eosinophil chemoattractants. Am J Respir Crit Care Med 2001; 164: 109-116
43. Sethi S, Muscarella K, Evans N, et al. Airway inflammation and etiology of acute exacerbations of chronic bronchitis. Chest 2000; 118: 1557-1565
44. Viglio S, Iadarola P, Lupi A, et al. MEKC of desmosine and isodesmosine in urine of chronic destructive lung disease patients. Eur Respir J 2000; 15: 1039-1045
45. Gompertz S, O'Brien C, Bayley DL, et al. Changes in bronchial inflammation during acute exacerbations of chronic bronchitis. Eur Respir J 2001; 17: 1112-1119
46. Gottlieb DJ, Stone PJ, Sparrow D, et al. Urinary desmosine excretion in smokers with and without rapid decline of lung function: the Normative Aging Study. Am J Respir Crit Care Med 1996; 154: 1290-1295
47. Andersson I, Johansson K, Larsson S, et al. Long-term oxygen therapy and quality of life in elderly patients hospitalised due to severe exacerbation of COPD. A 1 year follow-up study. Respir Med 2002; 96: 944-949
48. Seemungal TAR, Donaldson GC, Paul EA, et al. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 1418-1422
49. Xu W, Collet JP, Shapiro S, et al. Negative impact of unreported COPD exacerbations on health-related quality of life at 1 year. Eur Respir J 2010; 35: 1022-1030
50. Garcia-Aymerich J, Lange P, Benet M, et al. Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort study. Thorax 2006; 61: 772-778
51. Haughney J, Partridge MR, Vogelmeier C, et al. Exacerbations of COPD: quantifying the patient's perspective using discrete choice modelling. Eur Respir J 2005; 26: 623-629
52. Kessler R, Stahl E, Vogelmeier C, et al. Patient understanding, detection and experience of COPD exacerbations. An observa- tional, interview-based study. Chest 2006; 130: 133-142
53. Hopkinson NS, Tennant RC, Dayer MJ, et al. A prospective study of decline in fat free mass and skeletal muscle strength in chronic obstructive pulmonary disease. Respir Res 2007; 8: 25
54. Pitta F, Troosters T, Probst VS, et al. Physical activity and hospitalization for exacerbations of COPD. Chest 2006; 129: 536-544
55. Cote C, Dordelly LJ, Celli BR. Impact of COPD exacerbations on patient-centered outcomes. Chest 2007; 131: 696-704
56. Miravitlles M, Jardim JR, Zitto T, et al. Pharmacoeconomic study of antibiotic therapy for acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease. Arch Bronconeumol 2003; 39: 549-553
57. Friedman M, Hilleman DE. Economic burden of chronic obstruc- tive pulmonary disease. Pharmacoeconomics 2001; 19: 245-254
58. Almagro P, Calbo E, Ochoa de Echaguen A, et al. Mortality after hospitalization for COPD. Chest 2002; 121: 1441-1448
59. Groenewegen KH, Schols AM, Wouters EF. Mortality and mortality-related factors after hospitalization for acute exacerba- tion of COPD. Chest 2003; 124: 459-467
60. Fuso L, Incalzi RA, Pistelli R, et al. Predicting mortality of patients hospitalized for acute exacerbated chronic obstructive pulmonary disease. Am J Med 1995; 98: 272-277
61. Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P, et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005; 60: 925-931
62. Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999; 15: 957-965
63. Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once- daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Internal Med 2005; 143: 317-326
64. Dusser D, Bravo ML, Iacono P. The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur Respir J 2006; 27: 547-555
65. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543-1554
66. Hanania NA, Darken P, Horstman D, et al. The efficacy and safety of fluticasone propionate (250 mg)/salmeterol (50 mg) combined in the Diskus inhaler for the treatment of COPD. Chest 2003; 124: 834-843
67. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone proprionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-789
68. Ferguson GT, Anzueto A, Fei R, et al. Effect of fluticasone propionate/salmeterol (250/50 mg) or salmeterol (50 mg) on COPD exacerbations. Respir Med 2008; 102: 1099-1108
69. Anzueto A, Ferguson TG, Feldman G, et al. Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. J COPD 2009; 6: 320-329
70. Poole B, Black PM. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2010; 2: CD001287
71. Stey C, Steurer J, Bachmann S, et al. Efficacy of oral N- acetylcysteine in chronic bronchitis: a quantitative systematic review. Eur Respir J 2000; 16: 253-262
72. Gramdjean EM, Berthet P, Ruffmann R, et al. Efficacy of oral long- term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clin- ical trials. Clin Ther 2000; 22: 209-221
73. Zheng JP, Kang J, Huang SG, et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomized placebo-controlled study. Lancet 2008; 371: 2013-2018
74. Decramer M, Rutten-van MM, Dekhuijzen PN, et al. Effects of N- acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomized placebo-controlled trial. Lancet 2005; 365: 1552-1560
75. Miravitlles M. Prevention of exacerbations of COPD with pharma- cotherapy. Eur Respir Rev 2010; 19: 119-126
76. Decramer M, Janssens W. Mucoactive therapy in COPD. Eur Respir Rev 2010; 19: 134-140.